Collectively, these results not only suggest that the IL-6/IL-6R/STAT3 may be used as molecular targets for the inhibition of IL-6-induced EMT, but also provide experimental evidence for the potential use of metformin in the treatment of lung adenocarcinoma. This evidence concerns the gene STAT3 and lung adenocarcinoma.